Evaluation of sodium‐glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics

• Published in: The Kaohsiung journal of medical sciences 2023-04, Vol.39 (4), p.416-425
• Main Authors: Weng, Yi‐Fang, Chen, Chung‐Yu, Hwang, Shang‐Jyh, Huang, Yaw‐Bin
• Format: Article
• Language: English
• Subjects: Acute Kidney Injury; Adult; Analysis; Cardiac patients; Codes; Cohort analysis; Dapagliflozin; Dextrose; Diabetes; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetic retinopathy; Diuretics; Gender; Glucose; Heart failure; Heart Failure - complications; Heart Failure - drug therapy; Hospitals; Humans; Hypoglycemic Agents - pharmacology; Kidney diseases; Laboratories; Medical colleges; Medical prognosis; Mortality; Patient outcomes; Patients; Population; Prognosis; Retrospective Studies; SGLT2 inhibitors; Sodium; Sodium-Glucose Transporter 2 - metabolism; Surveys; Survival analysis; Type 2 diabetes; type 2 diabetes mellitus
• ISSN: 1607-551X; 2410-8650
• DOI: 10.1002/kjm2.12635

Previous studies about renal protection of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in type 2 diabetes mellitus (T2DM) patients with heart failure (HF) on diuretics were still limited. The goal of the study is to survey the efficacy of SGLT2i to reduce all‐cause mortality and renal impairments in patients with T2DM and HF using diuretics. The retrospective cohort study was analyzed from Kaohsiung Medical University Hospital Research Database (KMUHRD) in Taiwan. Adults with T2DM and HF using any diuretics at least 28 days during 2016–2018 were enrolled and then divided into the SGLT2i group and the non‐SGLT2i group. Propensity score matching was used to balance baseline characteristics between the two groups. The primary outcome was all‐cause mortality. Secondary outcomes contained dialysis occurrence, renal progression, and acute kidney injury (AKI). After 1:1 matching, there were 183 patients in each group respectively. When compared with the non‐SGLT2i group, the SGLT2i group had significantly lower all‐cause mortality (hazard ratios [HR]: 0.49, 95% CI 0.29–0.83, p = 0.008) and reduction of renal progression (HR: 0.30, 95% CI 0.12–0.75, p = 0.010). SGLT2i showed the trend to decrease dialysis occurrence (HR: 0.83, 95% CI 0.20–3.47, p = 0.797) and an increase in AKI (HR: 1.38, 95% CI 0.67–2.87, p = 0.383) but without significance. SGLT2 inhibitors were associated with reduced all‐cause mortality and less renal progression with significance in T2DM patients with HF on diuretics.